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Clustered regularly interspaced short
palindromic repeats (CRISPR)/Cas9 knockoutThe sigma-2 receptor (S2R) is a potential therapeutic target for cancer and neuronal diseases. However, the iden-
tity of the S2R has remained a matter of debate. Historically, the S2R has been deﬁned as (1) a binding site with
high afﬁnity to 1,3-di-o-tolylguanidine (DTG) and haloperidol but not to the selective sigma-1 receptor ligand
(+)-pentazocine, and (2) a protein of 18–21 kDa, as shown by speciﬁc photolabeling with [3H]-Azido-DTG
and [125I]-iodoazido-fenpropimorph ([125I]-IAF). Recently, the progesterone receptor membrane component 1
(PGRMC1), a 25 kDa protein, was reported to be the S2R (Nature Communications, 2011, 2:380). To conﬁrm
this identiﬁcation, we created PGRMC1 knockout NSC34 cell lines using the CRISPR/Cas9 technology. We found
that in NSC34 cells devoid of or overexpressing PGRMC1, the maximum [3H]-DTG binding to the S2R (Bmax) as
well as the DTG-protectable [125I]-IAF photolabeling of the S2R were similar to those of wild-type control cells.
Furthermore, the afﬁnities of DTG and haloperidol for PGRMC1 (KI = 472 μM and 350 μM, respectively), as
determined in competition with [3H]-progesterone, were more than 3 orders of magnitude lower than those
reported for the S2R (20–80 nM). These results clarify that PGRMC1 and the S2R are distinct binding sites
expressed by different genes.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Recently there has been a resurgence of interest in sigma receptors.
Sigma binding sites were classiﬁed into Sigma-1 (S1R) and Sigma-2
(S2R) receptors based on earlier pharmacological studies (Bowen
et al., 1989; Hellewell and Bowen, 1990; Hellewell et al., 1994;
Quirion et al., 1992). While the S1R was cloned and has been shown
to play important roles in a plethora of tissues and cells, the molecular
identity of the S2R remains obscure (for review, see Matsumoto et al.
(2014)). Pharmacological and chemical biology studies have revealed
that the S2R is highly expressed in tumors and S2R ligands have
shown anti-cancer effects (Crawford and Bowen, 2002; Hornick et al.,
2010; Kashiwagi et al., 2009; Vilner and Bowen, 2000; Vilner et al.,, University ofWisconsin School
dison, WI 53705, United States.
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. This is an open access article under1995; Wheeler et al., 2000). In addition, the S2R is also implicated to
play an important role in the nervous system (Vilner and Bowen,
1993; Vilner and Bowen, 2000). However, the lack of a known S2R
amino acid sequence is greatly impeding progress in identifying S2R's
biological functions as well as potential therapeutic methods targeting
this receptor. It is thus imperative to discover its genetic identity.
Sigma receptors are arguably the most mysterious signaling pro-
teins. While the S1R was mischaracterized as an opioid receptor
(Martin et al., 1976) until its gene sequence became available (Hanner
et al., 1996), the S2R has evaded many attempts to decipher its genetic
coding. For example, mass spectrometry data suggested histones or as-
sociated proteins as S2R ligand binding proteins (Colabufo et al., 2006),
but they differ from the S2R in membrane association. The difﬁculty in
unveiling the S2R molecular identity may stem from the fact that it re-
sides in lipid rafts and is not readily detergent-extractable without
compromising its functional integrity (Gebreselassie and Bowen,
2004).Moreover, the abundance of this protein inmembranes prepared
from mammalian tissues is extremely low (e.g. 0.1 μg/mg total protein,
Ruoho et al., unpublished data).
The S2R has been historically deﬁned as a binding site with high-
afﬁnity (20–80 nM) for DTG (1,3-di-o-tolylguanidine) and haloperidolthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Its molecular size was shown to be 18–21 kDa by [3H]-Azido-DTG
photoafﬁnity labeling (Hellewell and Bowen, 1990; Bowen et al.,
1989). To readily “visualize” the S2R, our group developed a highly sen-
sitive photoafﬁnity probe, [125I]-iodoazido-fenpropimorph ([125I]-IAF)
(Pal et al., 2007). In accordance with the [3H]-Azido-DTG photolabeling
data (Hellewell and Bowen, 1990; Hellewell et al., 1994), the [125I]-IAF
photolabeled S2R band appears at ~18 kDa on a SDS gel. Importantly,
this S2R band is protected by DTG and haloperidol but not (+)-pentaz-
ocine, a speciﬁc S1R ligand. Using this chemical biology method we
have been able to discriminatively detect the S2R and S1R and their
speciﬁcity for novel sigma receptor ligands (Pal et al., 2007; Fontanilla
et al., 2009; Fontanilla et al., 2008).
A recent ﬁnding by Xu et al. identiﬁed progesterone receptor mem-
brane component-1 (PGRMC1) as the S2R (Xu et al., 2011). While this
discovery is expected to open broad-spectrumopportunities in research
and/or the development of therapeutic interventions given the func-
tional importance of the S2R, critical questions remain. First, the appar-
ent molecular weight of PGRMC1 on SDS gels is 25 kDa rather than 18–
21 kDa as previously reported for the S2R (Pal et al., 2007; Hellewell and
Bowen, 1990). Our earlier studies using [125I]-IAF showed only two DTG
(or haloperidol)-protectable photolabeled bands on the SDS gel, namely
the S2R and the S1R. We did not detect an ~25-kDa band that is consis-
tent with PGRMC1 (Ruoho et al., 2013; Fontanilla et al., 2009; Pal et al.,
2007), not even with PGRMC1 overexpressed (Chu et al., 2015; Ruoho
et al., 2013). Second and more importantly, a high-afﬁnity (20–
80 nM) binding with DTG or haloperidol is the signature of the S2R,
but the DTG (or haloperidol) binding afﬁnity for PGRMC1 has never
been reported. It is worth noting that in spite of this ambiguity, percep-
tion of PGRMC1 as the S2R has become increasingly accepted among
researchers working on PGRMC1 (Mir et al., 2013; Bali et al., 2013;
Izzo et al., 2014). It is therefore important to clarify whether PGRMC1
is truly the S2R. In this study, we aimed to explicitly answer two key
questions: 1) is the S2R a splice variant of PGRMC1 and 2) does
PGRMC1 bindwith high afﬁnity to DTG and haloperidol— the signature
of the S2R.
2. Methods
2.1. Reagents
CM compounds were synthesized in the McCurdy Lab (University of
Mississippi, University, MS). [3H]-(+)-1,3-ditolyl guanidine (DTG) and
[3H]-progesterone were obtained from PerkinElmer, (Waltham, MA).
Nonradioactive DTG, haloperidol, (+)-pentazocine and progesterone
were obtained from Sigma-Aldrich (St. Louis, MO). Rabbit anti-
PGRMC1 antibody was purchased from Proteintech (Chicago, IL; Cat.
No. 12990-1-AP). PGRMC1 cDNAwas obtained fromOrigene (Rockville,
MD). All other reagents were from Sigma-Aldrich or Thermo-Fisher un-
less speciﬁcally stated.
2.2. Cell Culture
NSC34 cells were grown in 15 cm cell culture dishes in 50%/50%
DMEM/F12 supplemented with 10% fetal bovine serum and 1×
penicillin/streptomycin (ﬁnal 100 μg/ml). PC12 cells were grown in
RPMI 1640 (Mediatech, Manassas, VA) supplemented with 10% heat-
inactivated horse serum (Corning, Manassas, VA), 5% fetal bovine
serum, and 1× penicillin/streptomycin.
2.3. Generation of CRISPR/Cas9 Constructs for PGRMC1 Knockout
For knocking out PGRMC1 using the clustered regularly interspaced
short palindromic repeats (CRISPR)/Cas9 technology, sgRNAs targeting
PGRMC1 exon-1 were cloned into a Cas9-expressing lentiviral transfer
vector (lentiCRISPRv2, Cat No. 52961, Addgene, Cambridge, MA)following the methods of the Feng Zhang laboratory (Sanjana et al.,
2014). Shown below are the two oligonucleotides from the sense
strands (clones 38 and 207) that were used for sgRNAs to target
PGRMC1 exon-1.
#38: 5′-ACCCGAGCGAGCTAGAGGGC-3′.
#207: 5′-CAAGCGGCGCGACTTCACCC-3′.
Oligonucleotides for the sgRNA guide sequence (both sense and an-
tisense strands) were synthesized at the Biotechnology Center, Univer-
sity of Wisconsin — Madison. sgRNA oligos were ﬁrst phosphorylated
using polynucleotide kinase (Life Technologies, Grand Island, NY) at
37 °C for 30 min and then annealed (sense to antisense strands) at 95
°C for 5 min and then ramp down to 25 °C at 5 °C/min. To prepare
LentiCRISPRv2 for insertion of oligos, LentiCRISPRv2 was digested and
dephosphorylatedwith FastDigest BsmBI and FastAP (Life Technologies,
Grand Island, NY) at 37 °C for 2 h. To insert the sgRNA annealed oligos
into digested/dephosphorylated LentiCRISPRv2, oligos were ligated
into the plasmid using T7 ligase (Enzymatics, Beverly, MA) at 25 °C for
5 min. Cloned transfer plasmids were ampliﬁed using an endotoxin-
free midi-prep kit (Qiagen, Valencia, CA).2.4. Packaging of Lentiviruses
To prepare lentiviruses for PGRMC1 knockout, each of the two
LentiCRISPRv2–sgRNA PGRMC1 (#38 and #207) transfer plasmids was
co-transfected with packaging plasmids pMD2.G and psPAX2 (Addgene
plasmids 12259 and 12260), as described previously (Zufferey et al.,
1998). Brieﬂy, HEK293T cells (ATCC CRL-3216) at 80% conﬂuency in a
35-mm dish were transfected with 2 μg of the transfer plasmid, 0.2 μg
of pMD2.G, and 0.75 μg of psPAX2, in DMEM (Life Technologies, Grand
Island, NY) added with 10% fetal bovine serum (Hyclone, Logan, Utah)
and 4 μl of JetPrime transfection reagent (POLYPLUS-TRANSFECTION
Inc., NY). After 72 h, the supernatant was harvested and centrifuged at
3000 rpm at 4 °C for 10 min to pellet cell debris. The virus-containing
supernatant was ﬁltered through a 0.45 μm low protein binding mem-
brane (Millipore, Billerica, MA) and used immediately for creating
PGRMC1 knockout cell lines.2.5. Lentiviral Transduction for PGRMC1 Knockout
For viral transduction to knockout PGRMC1, ~2.5 × 104 NSC34 cells
were incubated with the foregoing ﬁltered lentivirus-containing
supernatant. After 3 days of transduction, puromycin was added
(ﬁnal 3 μg/ml) to screen sgRNA/Cas9 positive cells. Two weeks
later the cell culturewas expanded to three 35-mmdishes. In order to as-
sess the efﬁciency of sgRNA-guided Cas9 cutting in the PGRMC1genomic
sequence (exon-1), genomic DNAwas extracted for PCR ampliﬁcation of
the speciﬁc region including the sgRNA/Cas9 excision site. Forward
primer: gcggaggaagcggactgttc; reverse primer: agcgggccgggggcacgagg.
PCR products were digested with 1 μl T7 Endonuclease I (New England
Biolabs Inc., MA) for 2 h at room temperature, and then subjected to
electrophoresis in a 1.5% agarose gel. PGRMC1 protein knockout was
conﬁrmed by Western blotting using a PGRMC1 speciﬁc antibody.2.6. Construct of pCI/Neo-PGRMC1-3xHA for PGRMC1 Overexpression
Full-length PGRMC1was engineered to contain a C-terminal 3 × HA
tag through polymerase chain reaction (PCR)-engineered MluI restric-
tion enzyme site that replaced the native stop codon. PCR ampliﬁed
PGRMC1 was placed between NheI and MluI restriction enzyme sites
and the 3 × HA tag was inserted between MluI and NotI restriction
enzyme sites on a pCI/neo vector (Promega, Madison, WI). The pCI/
Neo-PGRMC1-3 × HA clone was conﬁrmed by sequencing at the
Biotechnology Center, University of Wisconsin — Madison. A pCI/neo
vector without the PGRMC1 gene served as control.
1808 U.B. Chu et al. / EBioMedicine 2 (2015) 1806–18132.7. Plasmid Transfection
To overexpress PGRMC1, NSC34 cells were grown to 70–80%
conﬂuency before transfectionwith pCI/Neo PGRMC1-3 ×HA. Transfec-
tionwas carried out using Lipofectamine 2000 (Life Science Technology,
Grand Island, NY) according to the manufacturer's instruction. Three
15-cm dishes were used for each condition. Control cells were
transfected with the same amount of the pCI/neo plasmid that does
not contain the PGRMC1 gene. Forty-eight hours post-transfection,
culture media were removed; cells were washed twice with ice-cold
PBS and then scraped from culture dishes. Cells were pelleted by centri-
fugation at 500 ×g for 5 min and used immediately for membrane
preparations.
2.8. Preparation of NSC34 and PC12 Cell Membranes
Cellmembrane preparationwas performed following our established
method (Guo et al., 2012). Brieﬂy, cell pelletswere suspended in PBS and
sonicated on ice using the following settings: 5 sets (10 strokes/set) at
duty cycle = 50, output control = 5. Cell homogenates were centri-
fuged at 8000 ×g for 10min, and the resulting supernatant was collect-
ed and subjected to ultracentrifugation at 100,000 ×g for 1 h. The
supernatant was discarded and the pellet was gently washed twice
with ice-cold PBS. The pellet was then resuspended in PBS and sonicat-
ed (3 sets, 10 strokes/set at duty cycle = 50, output control = 5) to
homogeneity. Protein concentration was then measured using the
standard Bradford reagent (Sigma-Aldrich, St. Louis, MO).
2.9. Preparation of Rat Liver Membranes
Rat liver membranes, a rich source of sigma-2 receptor, were pre-
pared as described in our previous reports (Pal et al., 2007; Guo et al.,
2012) from frozen tissues (Pel Freez Biologicals, Rogers, AR). Liver tis-
sues were homogenized (10 ml buffer/g wet tissue) by 4 bursts of 10 s
each using a Brinkman polytron (American Laboratory Trading Inc.,
East Lyme, CT) on setting 6 in ice-cold sodium phosphate buffer
(10mMpH7.4) containing 0.32M sucrose and a cocktail of protease in-
hibitors (20 μg/ml leupeptin, 5 μg/ml soybean trypsin inhibitor, 100 μM
phenylmethylsulfonyl ﬂuoride (PMSF), 100 μMbenzamidine and 1mM
EDTA). The membrane suspension after homogenization was centri-
fuged for 10 min at 17,000 ×g and the supernatant was subjected to ul-
tracentrifugation at 100,000 ×g for 1 h to collect membrane fractions.
The pellet from the second centrifugation was resuspended to a protein
concentration of 10 mg/ml in the foregoing buffer, snapped frozen and
stored at−80 °C.
2.10. Western Blot Analyses
Protein samples (membranes from Control, PGRMC1 knockout, and
PGRMC1 overexpressingNSC34 cells) of 25 μg eachwere separated on a
12% SDS gel at 140 V. Proteins were transferred to a polyvinyldiﬂuoride
(PVDF) membrane (Millipore, Billerica, Massachusett, 0.45 μm) in Tris–
Glycine Buffer (25 nMTris-Base, 200mMGlycine) at 40 V for 3 h at 4 °C.
The PVDF membrane was blocked with 5% non-fat dry milk in TBS con-
taining 0.1% Tween-20 (TBST) for 1 h at room temperature, incubated
with a rabbit anti-PGRMC1 antibody (Proteintech, Chicago, IL) over-
night at 4 °C, and thenwashed 3 times for 15min each in TBST followed
by incubation with anti-Rabbit IgG HRP for 1 h at room temperature.
After a thorough wash of the membrane the speciﬁc PGRMC1 band
was illuminated with chemiluminescence reagents (Millipore, Billerica,
MA).
2.11. Photolabeling With [125I]-Iodo-azido-fenpropimorph ([125I]-IAF)
The synthesis of [125I]-IAF and photolabeling was performed accord-
ing to our published method (Pal et al., 2007). For photolabelingexperiments, each membrane sample of 200 μg proteins was preincu-
bated with 20 μM 1,3-di-o-tolylguanidine (DTG), 5 μM (+)-pentazo-
cine, or various concentrations of CM compounds (Matsumoto et al.,
2014) in 50 mM Tris–HCL (pH 7.4) for 30 min at 32 °C. [125I]-IAF was
then added (ﬁnal 1 nM) and incubated for another 40 min with gentle
shaking in the dark. Photoactivation of [125I]-IAF was performed by ex-
posing the samples to a high-pressure AH-6 mercury lamp for 5 s and
Laemmli buffer was immediately added to each sample. The samples
were then resolved on a 16 × 18 cmSDS gel with 6–18% acrylamide gra-
dient. The gel was dried and exposed to a phosphor screen for 24–48 h
and autoradiograms were recorded using a Phosphoimager (Molecular
Dynamics).
2.12. Assay of Saturation Binding of [3H]-1,3-Di-tolylguanidine ([3H]-DTG)
Assays were performed according to Hellewell and Bowen (1990).
Membranes (28 μg total proteins per reaction) prepared from NSC34
cells of controls, PGRMC1 knockout, or PGRMC1-3 × HA overexpression
were incubated in 100 μl 50mMTris–HCL (pH8.0) containing a series of
concentrations (3 nm–300 nM) of [3H]-DTG for 90min at 37 °C. The re-
actions were terminated by rapid ﬁltration through glass ﬁber ﬁlters
(Whatman GF/B, Whatman, Maidstone, UK), using a Brandel cell
harvester (Brandel, Gaithersburg, MD). The glass ﬁber ﬁlters were pre-
soaked in 0.5% polyethyleneimine (Morris et al., 1991) for at least 1 h
at room temperature. Filters were washed 4 times with 4 ml of ice-
cold 50mMTris–HCL, pH 8.0. Radioactivity was quantiﬁed in a scintilla-
tion liquid (Ultima Gold, PerkinElmer, Waltham, MA) using a liquid
scintillation counter (Packard model 1600CA, Packard Instrument Co.,
Downers Grove, IL).
2.13. Inhibition of [3H]-DTG Binding to the S2R
Inhibition of [3H]-DTG binding to S2R was performed according to
Hellewell and Bowen (1990). Brieﬂy, rat liver membranes (28 μg total
proteins per reaction) were incubated in 100 μl 50 mM Tris–HCL
(pH 8.0) with 60 nM [3H]-DTG, 100 nM (+)-pentazocine to selectively
mask the sigma-1 receptor binding sites, and a series of concentrations
of an inhibitor to be tested. After incubation at 37 °C for 60 min, the re-
action was terminated by rapid ﬁltration through glass ﬁber ﬁlters,
using a Brandel cell harvester and processed as described above. IC50
valueswere then converted to KI values using the Cheng–Prusoff correc-
tion with the following equation KI = IC50 / (1 + [L] / KD) where [L] is
the ligand concentration of the radioactive molecule, and KD of [3H]-
DTG for the sigma-2 receptor was previously determined to be 60 nM
(Hellewell and Bowen, 1990). Nonspeciﬁc binding was monitored in
the presence of 10 μM nonradioactive haloperidol and subtracted from
total [3H]-DTG binding.
2.14. Inhibition of [3H]-Progesterone Binding to PGRMC1
Inhibition of [3H]-progesterone binding to PGRMC1 was performed
according to Peluso et al. (2008). Brieﬂy, rat liver membranes (14 μg
total proteins per reaction) were incubated in 100 μl 50 mM Tris–HCL
(pH 8.0) with 30 nM [3H]-progesterone, 100 nM (+)-pentazocine to
selectively mask the sigma-1 receptor binding sites, and a series of
concentrations of an inhibitor to be tested. After incubation at 37 °C
for 60 min, the reaction was terminated by rapid ﬁltration through
glass ﬁber ﬁlters, using a Brandel cell harvester and processed as de-
scribed above. IC50 values were then converted to KI values using the
Cheng–Prusoff correction with the following equation KI = IC50 /
(1 + [L] / KD) where [L] is the ligand concentration of the radioactive
molecule, and KD of [3H]-progesterone for PGRMC1 was previously
determined to be 30 nM. Nonspeciﬁc binding was monitored in the
presence of nonradioactive progesterone at 10 μM and subtracted from
total [3H]-progesterone binding.
Fig. 1. PGRMC1 knockout using a CRISPR/Cas9 approach. A. Schematic of the PGRMC1 sgRNA/Cas9-expressing lentiviral constructs for knocking out PGRMC1. Gray areas show the three
candidate sgRNA sequences in the exon-1 of the PGRMC1 gene, of which two were used for the CRISPR/Cas9 constructs. B. A representative DNA gel of control and PGRMC1 knockout
(clones 38 and 207) NSC34 cells verifying the Cas9 cleavage of the genomic DNA. Control refers to the NSC34 cells transfected with the control vector expressing Cas9 but not an
sgRNA. C. Western blotting detection of PGRMC1 in control and PGRMC1 knockout (clones 38 and 207) NSC34 cells.
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Data are presented as mean ± standard error of the mean (SEM).
Statistical analysis was conducted using two-tailed unpaired Student's
t-test. Data are considered statistically signiﬁcant when a P value is
b0.05.
3. Results
3.1. The S2R is not a Splice Variant of PGRMC1
The discrepancy in apparent molecular weight on SDS gels between
PGRMC1 (25 kDa) and the S2R (18–21 kDa) (Hellewell and Bowen,
1990; Pal et al., 2007) prompted us to determine whether the S2R is a
splice variant of PGRMC1. In order to address this question, we con-
structed a PGRMC1 knockout cell line using a CRISPR/Cas9 system
(Fig. 1A). Application of this new genome-editing technology is rapidly
expanding because of its effectiveness in completely depleting an en-
dogenous protein (Doudna and Charpentier, 2014), especially in con-
trast to siRNA knockdown, which is able to reduce a targeted protein
typically by 50–60%. Indeed, the two PGRMC1 knockout clones showed
complete and ~90% deletion of PGRMC1 protein, respectively, as esti-
mated by Western blotting (Fig. 1C). We then isolated membranes
from the wild-type control and knockout NSC34 cells and performed
[125I]-IAF photolabeling experiments following our previously pub-
lished method (Pal et al., 2007).
Because of the lack of a known S2R amino acid sequence, photo-
afﬁnity labeling has remained the most powerful approach to visual-
ize this receptor on a SDS gel (Hellewell and Bowen, 1990; HellewellFig. 2. [125I]-IAF photolabeling of the S2R is protected by S2R-speciﬁc ligands but not af-
fected by PGRMC1 knockout. A. [125I]-IAF photolabeling of the S2R in PC12 membranes
is protectable by CM compounds. [125I]-IAF photolabeling of both S1R and S2R was
protected by 20 μM DTG (D) while CM compounds (CM 353, CM 398, CM 775, and CM
777, see Fig. S1 for afﬁnities to sigma receptors) (Matsumoto et al., 2014) selectively
blocked the labeling of the S2R but not the S1R. Two concentrations (1 and 10 μM)
were used for CM compounds. B. [125I]-IAF photolabeling of the S2R in membranes pre-
pared from control and PGRMC1 knockout (clones 38 and 207) NSC34 cells. 5 μM (+)-
pentazocine (P) protected against [125I]-IAF photolabeling of the S1R while 20 μM DTG
(D) protected against photolabeling of both the S1R and the S2R. Note that the
background photolabeled bands were not protected by these speciﬁc sigma ligands.et al., 1994; Pal et al., 2007). The basic principle is to covalently
crosslink a photoactivatable S2R-binding probe to the receptor
such that the probe (radioactive- or ﬂuorescent-labeled) remains
with the protein even after denaturation with SDS. It is well known
that the S2R and S1R bind DTG with similar high afﬁnities
(~50 nM) but the S2R does not bind (+)-pentazocine which is a
high-afﬁnity ligand for the S1R (b10 nM) (Hellewell et al., 1994),
thus these two sigma receptors can be readily distinguished. Autora-
diography showed an [125I]-IAF photolabeled band of S1R at 26 kDa
which was protected by (+)-pentazocine and DTG (Fig. 2). The S2R
band appeared at ~18 kDa and was protected by DTG but not by
(+)-pentazocine (Fig. 2, A and B, see Fig. S1 for chemical structures
of ligands). We further tested the speciﬁcity of the [125I]-IAF
photoprobe using a group of ligands that possess superior binding afﬁn-
ity as well as selectivity towards the S2R (Fig. S1) (Matsumoto et al.,
2014), e.g. CM398 has a KI of 0.43 nM for the S2R in contrast to a KI of
560 nM for the S1R, as determined previously in competitive [3H]-
DTG binding assays (Matsumoto et al., 2014). An n-isothiocyanate de-
rivative (CM572) has been recently reported as an irreversible selective
afﬁnity label for the S2R (Nicholson et al., 2015). As shown in Fig. 2B,
these CM compounds at 1 μM completely blocked photolabeling of the
S2R without reducing the S1R labeling intensity, further validating
[125I]-IAF photolabeling as a highly speciﬁc approach for detection of
the S2R. It is noteworthy that an unidentiﬁed protein of ~20 kDa was
also photolabeled, but the labeling was not protected by any of the
foregoing S1R and S2R ligands (Fig. 2). This result provides another
line of evidence for the speciﬁcity of [125I]-IAF photolabeling of sigma
receptors.
Most interestingly, the comparison of [125I]-IAF photolabeling be-
tween control and two PGRMC1 knockout clones showed two clear re-
sults. First, the photolabeled S2R band was not diminished in the
knockout clones compared to the control. Second, there was not a
DTG-protectable photolabeled band consistent with endogenousFig. 3. Eliminating PGRMC1 protein does not alter [3H]-DTG binding to the S2R in cell
membranes. A. A representative of [3H]-DTG saturation binding in membranes prepared
from control and PGRMC1 knockout (clones 38 and 207) NSC34 cells, (+)-pentazocine
(100 nM) was included to mask [3H]-DTG binding to the S1R such that [3H]-DTG would
be bound only to the S2R and measured as speciﬁc S2R binding. Nonspeciﬁc binding
was measured (by adding haloperidol) and subtracted. Control refers to the NSC34 cells
transfected with the control vector for the expression of Cas9 but not an sgRNA. B. Statis-
tics. Maximum binding (Bmax) and equilibrium dissociation constants (KD) for [3H]-DTG
were calculated using a Prizm software and reported as mean ± SEM of three separate
experiments each performed in triplicates. Not signiﬁcant (n.s.).
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S1R and the S2R (Fig. 2A). While the S1R also migrated at ~25 kDa,
this photolabeled band was readily protected by (+)-pentazocine.
(+)-Pentazocine is not a ligand for PGRMC1, as indicated in Xu
et al. (Xu et al., 2011), thus precluding the possibility of this promi-
nent band being PGRMC1. Moreover, a lack of inﬂuence of PGRMC1
knockout on photolabeling of the S2R indicated that the existence
of a S2R ligand-binding pocket formed by a PGRMC1/S2R complex
is unlikely. Taken together, these results demonstrate that the S2R
is not a splice variant of PGRMC1 and thus these two proteins are
derived from different genes.
3.2. Neither Knockout nor Overexpression of PGRMC1Altered [3H]-DTG/S2R
Binding Characteristics
While the foregoing data indicated that PGRMC1 knockout did not
affect [125I]-IAF photolabeling of the S2R, we cautioned that, alternative-
ly, PGRMC1may be another DTG-binding protein that does not bind the
photoprobe [125I]-IAF. To test a correlation between PGRMC1 expres-
sion levels and [3H]-DTG binding, we performed [3H]-DTG saturation
binding assays using membranes prepared from wild type control and
PGRMC1 knockout cells. Thus far the only known high-afﬁnity DTGFig. 4. PGRMC1 overexpression does not change [3H]-DTG binding to the S2R in cellmembranes
and PGRMC1-3 × HA overexpressing NSC34 cells. Control refers to the NSC34 cells transfected w
iment of [3H]-DTG saturation binding (as described in Fig. 3A) in membranes prepared from c
(Bmax) and equilibrium dissociation constants (KD) for [3H]-DTG were calculated using a Prizm
in triplicates. Not signiﬁcant (n.s.).binding sites are the S2R and S1R, both with KD values for DTG in a
range of ~20–80 nM (depending on sources of membranes and
assay methods) (Weber et al., 1986; Quirion et al., 1992; Itzhak and
Kassim, 1990; Itzhak, 1987). Therefore the accepted radioligand
binding assays for the S2R involve using [3H]-DTG in the presence
of 100 nM (+)-pentazocine to mask the S1R binding site (Quirion
et al., 1992). As shown in Fig. 3A, [3H]-DTGbinding curves of the control
and two knockout clones were almost identical. Statistical analyses in-
dicated that neither Bmax nor KD was signiﬁcantly different between
control and knockout, which holds true for both of the PGRMC1 knock-
out clones (Fig. 3B). Thus, these results demonstrate that DTG binding
(to the S2R) characteristics in cell membranes do not correlate with
PGRMC1 protein levels. A disconnect between the S2R and PGRMC1
was also evidenced in our preliminary studies (Ruoho et al., 2013;
Chu et al., 2015) as well as a new report by Abate et al. using MCF-7
cells (Abate et al., 2015).
Furthermore, we also performed [3H]-DTG saturation binding assays
in a gain-of-function experiment using PGRMC1-HA over-expressed in
NSC34 cells. We infer that if PGRMC1 were a high-afﬁnity DTG binding
site, elevation of PGRMC1 protein levels would increasemaximum [3H]-
DTG binding. Remarkably, our data show that neither the Bmax nor KD
changed signiﬁcantly in response to PGRMC1 overexpression (Fig. 4).. A. A representativeWestern blot detecting PGRMC1 inmembranes prepared from control
ith the same expression vector but without the PGRMC1 gene. B. A representative exper-
ontrol and PGRMC1-3 × HA overexpressing NSC34 cells. C. Statistics. Maximum binding
software and reported as mean ± SEM of three separate experiments each performed
Fig. 6. Assessment of progesterone and haloperidol binding afﬁnities for the S2R. Experi-
mentswere performedwith rat livermembranes. Shown on the left is a representative in-
hibition curve of [3H]-DTG binding (at 60 nM) to the S2R in the presence of increasing
concentrations of non-radioactive progesterone or haloperidol. Nonspeciﬁc binding was
measured by the addition of 10 μM of nonradioactive haloperidol and subtracted.
Inhibition constants (KI) are reported as mean ± SEM from 3 separate experiments each
performed in triplicates.
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high afﬁnity [3H]-DTG binding to the S2R.
3.3. PGRMC1 is not a High-afﬁnity DTG Binding Site
Xu et al. showed that DTG at 1 μM protected the photolabeling of
PGRMC1 (with WC-21) (Xu et al., 2011), however the afﬁnity of DTG
for PGRMC1 was not reported. To directly address whether DTG binds
to PGRMC1with high afﬁnity, we performed competitive binding assays
with a ﬁxed low concentration of [3H]-progesterone (30 nM) and in-
creasing concentrations of unlabeled DTG. Progesterone is known to
be a high-afﬁnity (KD = 35 nM) ligand for PGRMC1 (Peluso et al.,
2008). At 30 nM, the S2R is not expected to bind progesterone because
the KI of progesterone for the S2R is 14.2 ± 4.9 μM in rat liver mem-
branes (Fig. 6). Thus, high-afﬁnity [3H]-progesterone binding serves as
a discriminative tool for the detection of PGRMC1, providing a unique
opportunity for us to assess the DTG and haloperidol binding afﬁnities
for PGRMC1.
As shown in Fig. 5, the KI of DTG and haloperidol for PGRMC1 in rat
liver membranes were determined to be 472 ± 420 μM and 350 ±
19 μM, respectively. In stark contrast, the afﬁnities of DTG (20–80 nM)
(Vilner et al., 1995; Hellewell et al., 1994; Matsumoto et al., 2014) and
haloperidol (31.5±0.5 nM, Fig. 6) for the S2R are several orders ofmag-
nitude higher in the same (rat liver) membranes further supporting a
lack of correlation between PGRMC1 and the S2R binding site. Con-
versely, progesterone, a classic high-afﬁnity (KD = 35 nM) ligand of
PGRMC1 (Peluso et al., 2008), showed a very low afﬁnity for the S2R
in rat liver membranes (KI = 14.2 ± 4.9 μM, Fig. 6). Thus, these results
present further compelling evidence for the conclusion that PGRMC1
and the S2R are two different binding sites.
4. Discussion
As a potential target for tumor diagnosis and treatment, the S2R has
been the subject ofmany studies, but its identity has remained amystery.
While PGRMC1 was recently reported to be the S2R (Xu et al., 2011), in-
consistency remains in their key characteristics. In order to resolve the
ambiguity of genetic and pharmacological relationships between
PGRMC1 and the S2R, we ﬁrst determined whether PGRMC1 and the
S2R are derived from the same gene. Through CRISPR/Cas9-mediated
genome-editing (Cong et al., 2013), we knocked out PGRMC1 in a
motor neuron-like cell line (NSC34). We found that [125I]-IAF
photolabeling of the S2R and [3H]-DTG/S2R binding characteristics
remained unchanged in the PGRMC1 knockout versus the wild typeFig. 5. Assessment of DTG and haloperidol binding afﬁnities for PGRMC1. Experiments
were performedwith rat livermembranes. Shown on the left is a representative inhibition
curve of [3H]-progesterone binding (at 30 nM) to PGRMC1 in the presence of increasing
concentrations of non-radioactive DTG or haloperidol. Nonspeciﬁc binding wasmeasured
by the addition of 10 μM of nonradioactive progesterone and subtracted, as previously
described by Peluso et al. (2008). Inhibition constants (KI) are reported as mean ± SEM
from three separate experiments each performed in triplicates for DTG and two separate
experiments each performed in triplicates for haloperidol.control. These data indicate that PGRMC1 and S2R are genetically two dif-
ferent proteins. Second, we determined the inhibition constant (KI) of
DTG and haloperidol for binding to PGRMC1 using [3H]-progesterone at
its reported KD of 35 nM for PGRMC1 (Peluso et al., 2008). The afﬁnities
of DTG and haloperidol for PGRMC1 in rat liver membranes were found
to be 472 ± 420 μM and 350 ± 19 μM, respectively. These DTG and hal-
operidol KI values for PGRMC1 are N3 orders of magnitude higher than
their KI values for the S2R in the same membranes (20–80 nM) (Vilner
et al., 1995; Hellewell et al., 1994; Matsumoto et al., 2014). This striking
difference indicates that PGRMC1 does not have the signature pharmaco-
logical characteristics that have been associated with the S2R in the liter-
ature (i.e. tight binding to DTG and haloperidol) (Bowen et al., 1989;
Hellewell and Bowen, 1990; Hellewell et al., 1994). Therefore, PGRMC1
is a non-S2R binding site in mammalian tissues.
Based on the original discoveries, the S2R has been authentically
deﬁned as a high-afﬁnity DTG binding site with a molecular weight at
18–21 kDa (Bowen et al., 1989; Hellewell and Bowen, 1990; Hellewell
et al., 1994; Itzhak, 1987;Weber et al., 1986). According to this deﬁnition,
the results presented here indicate that PGRMC1 is not the true, long
sought-after S2R. This conclusion is supported by several lines of evi-
dence: 1) PGRMC1 is a 25 kDa protein whereas the S2R has been deter-
mined to be 18–21 kDa by photolabeling (Hellewell and Bowen, 1990;
Hellewell et al., 1994; Pal et al., 2007). 2) PGRMC1 knockout did not re-
duce [125I]-IAF photolabeling of the S2R (18–21 kDa band) that was pro-
tectable by DTG and the highly S2R-selective CM compounds. 3) Either
knockout or overexpression of PGRMC1 did not signiﬁcantly alter [3H]-
DTG binding to the S2R in NSC34 cell membranes (Fig. 3) or HEK293
cell membranes (Abate et al., 2015). These lines of evidence demonstrate
that PGRMC1 and the S2R are expressed by different genes. 4) Most im-
portantly, the DTG (and haloperidol) afﬁnity for PGRMC1 is more than
three orders of magnitude lower than that determined for the S2R in rat
liver membranes, indicating that PGRMC1 is not the S2R ligand binding
site. Thus, taken together previous studies and the data presented here-
with, it is premature to equate PGRMC1 to the S2R (Izzo et al., 2014). Fur-
ther research is needed to discover the S2R sequence followed by careful
biochemical, pharmacological and functional veriﬁcations.
In summary, through genome editing in combination with chemical
biology uniquely tailored for characterization of the S2R, we have ad-
dressed the questions critically important with regard to the true identity
of the S2R. We found that (1) PGRMC1 and the S2R are derived from dif-
ferent genes; (2) PGRMC1 is not a high-afﬁnityDTGandhaloperidol bind-
ing site. In others words, PGRMC1 is not the originally deﬁned S2R. This
clariﬁcation may impact the research community as follows: 1) Since
the S2R has been found to be functionally important in cancer and neuro-
nal diseases (Cassano et al., 2006; Crawford and Bowen, 2002; Kashiwagi
1813U.B. Chu et al. / EBioMedicine 2 (2015) 1806–1813et al., 2009; Vilner and Bowen, 2000; Vilner et al., 1995; Wheeler et al.,
2000), the ﬁndings reported herein pose a timely reminder that the
true, high-afﬁnity DTG binding S2R has yet to be cloned. 2) Our study
will help clarify confounding messages resulting from the premature
conclusion that PGRMC1 is the S2R (Xu et al., 2011). For example, a pro-
autophagy function has recently been attributed to the S2R, based on
studies on PGRMC1 (Mir et al., 2013), but whether the true S2R is
responsible for autophagy or not remains unknown. 3) Recognizing that
PGRMC1 and the S2R are different binding sites is critical for rational
drug design and development of therapeutic molecules, since targeting
PGRMC1 may not necessarily produce the same functional outcomes as
targeting the S2R in animal models or human patients. Thus, the results
presented here underscore the necessity of more careful studies on the
S2R and an urgent need to decode the sequence of this intriguing
receptor.
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